With Bioelectronics, disease will be treated by small implantable devices that can modify electrical nerve signals. The aim is to modulate irregular or altered impulses that occur in many illnesses.
A GSK representative, Famm said the first generation of implants coming to market would be around the size of a medical pill but the aim eventually was to make them as small or smaller than a grain of rice, using the latest advances in nanotechnology.
GSK believes chronic conditions such as diabetes, arthritis and asthma could be treated using these tiny devices, which consist of a electronic collar that wraps around nerves.
GSK and Google together will contribute 540 million pounds ($715 million) over seven years (2023) to Galvani Bioelectronics, they said on Monday.
YouTube Channel: Health Then More